Abstract
A retrospective analysis of data from the Mayo Clinic's Tapestry trial shows that whole-exome sequencing is an effective tool to identify people with hereditary breast and ovarian cancer syndrome and Lynch syndrome. The study also revealed that nearly 40% of these people, despite their cancer risk, would not qualify for preventive screening under current National Comprehensive Cancer Network guidelines.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.